Treating EGFR mutation resistance in non-small cell lung cancer – role of osimertinib
V Mazza, F Cappuzzo - The application of clinical genetics, 2017 - Taylor & Francis
The discovery of mutations in EGFR significantly changed the treatment paradigm of patients
with EGFR-mutant non-small cell lung cancer (NSCLC), a particular group of patients with …
with EGFR-mutant non-small cell lung cancer (NSCLC), a particular group of patients with …
Role of osimertinib in the treatment of EGFR-mutation positive non-small-cell lung cancer
JW Carlisle, SS Ramalingam - Future oncology, 2019 - Taylor & Francis
Mutations in the EGFR occur in approximately 10–35% of non-small-cell lung cancer
(NSCLC) patients. Osimertinib is a third-generation oral small molecule inhibitor of EGFR …
(NSCLC) patients. Osimertinib is a third-generation oral small molecule inhibitor of EGFR …
[HTML][HTML] Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer
Y Li, T Mao, J Wang, H Zheng, Z Hu, P Cao… - Cell Communication and …, 2023 - Springer
Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) is currently the
standard first-line therapy for EGFR-mutated advanced non-small cell lung cancer (NSCLC) …
standard first-line therapy for EGFR-mutated advanced non-small cell lung cancer (NSCLC) …
Osimertinib for EGFR T790M mutation-positive non-small cell lung cancer
K Soejima, H Yasuda, T Hirano - Expert review of clinical …, 2017 - Taylor & Francis
Introduction: Significant advances have been made since the development of epidermal
growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) targeting EGFR mutations in …
growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) targeting EGFR mutations in …
Impact of EGFR genotype on the efficacy of osimertinib in EGFR tyrosine kinase inhibitor-resistant patients with non-small cell lung cancer: a prospective …
S Igawa, T Ono, M Kasajima, M Ishihara… - Cancer Management …, 2019 - Taylor & Francis
Purpose: A T790M of the epidermal growth factor receptor (EGFR) is the most frequently
encountered mutation conferring acquired resistance to EGFR tyrosine kinase inhibitors …
encountered mutation conferring acquired resistance to EGFR tyrosine kinase inhibitors …
[HTML][HTML] The study of primary and acquired resistance to first-line osimertinib to improve the outcome of EGFR-mutated advanced Non-small cell lung cancer patients …
A Ferro, GM Marinato, C Mulargiu, M Marino… - Critical Reviews in …, 2024 - Elsevier
The development of targeted therapy in epidermal growth factor receptor (EGFR)-mutated
non-small cell lung cancer (NSCLC) patients has radically changed their clinical …
non-small cell lung cancer (NSCLC) patients has radically changed their clinical …
[HTML][HTML] Acquired Resistance to Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer: How Do We Overcome It?
E Bertoli, E De Carlo, A Del Conte, B Stanzione… - International Journal of …, 2022 - mdpi.com
Osimertinib is currently the preferred first-line therapy in patients with non-small cell lung
cancer (NSCLC) with common epidermal growth factor receptor (EGFR) mutation and the …
cancer (NSCLC) with common epidermal growth factor receptor (EGFR) mutation and the …
Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy
M Santarpia, A Liguori, N Karachaliou… - Lung Cancer: Targets …, 2017 - Taylor & Francis
The discovery of epidermal growth factor receptor (EGFR) mutations and subsequent
demonstration of the efficacy of genotype-directed therapies with EGFR tyrosine kinase …
demonstration of the efficacy of genotype-directed therapies with EGFR tyrosine kinase …
[HTML][HTML] The resistance to EGFR-TKIs in non-small cell lung cancer: from molecular mechanisms to clinical application of new therapeutic strategies
C Laface, FM Maselli, AN Santoro, ML Iaia, F Ambrogio… - Pharmaceutics, 2023 - mdpi.com
Almost 17% of Western patients affected by non-small cell lung cancer (NSCLC) have an
activating epidermal growth factor receptor (EGFR) gene mutation. Del19 and L858R are the …
activating epidermal growth factor receptor (EGFR) gene mutation. Del19 and L858R are the …
Next-generation sequencing based mutation profiling reveals heterogeneity of clinical response and resistance to osimertinib
J Zhao, G Lin, M Zhuo, Z Fan, L Miao, L Chen, A Zeng… - Lung Cancer, 2020 - Elsevier
Objectives The 3rd generation epidermal growth factor receptor-tyrosine kinase inhibitor
(EGFR TKI) osimertinib has shown promising efficacy both in EGFR-mutant, T790M positive …
(EGFR TKI) osimertinib has shown promising efficacy both in EGFR-mutant, T790M positive …